Expert Insights Quiz
Prodromal Symptoms of Schizophrenia
FDA Alerts
11/16/2026
Maria Mantas
The FDA approved dexmedetomidine (IGALMI) sublingual film for at-home treatment of agitation associated with schizophrenia, schizoaffective disorder, and bipolar disorders.
The FDA approved dexmedetomidine (IGALMI) sublingual film for at-home treatment of agitation associated with schizophrenia, schizoaffective disorder, and bipolar disorders.
The FDA approved dexmedetomidine...
11/16/2026
Psych Congress Network
Research Summary
10/15/2026
Maria Mantas
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data meta-analysis of 18 fixed-dose trials involving 7062 adults with acute schizophrenia found no evidence of sex differences in antipsychotic efficacy for overall symptom improvement.
An individual participant data...
10/15/2026
Psych Congress Network
FDA Alerts
10/09/2026
Brionna Mendoza
Teva Pharmaceuticals announced the FDA approval of subcutaneous olanzapine (Weltruza) for extended-release injectable suspension on October 9, 2026.
Teva Pharmaceuticals announced the FDA approval of subcutaneous olanzapine (Weltruza) for extended-release injectable suspension on October 9, 2026.
Teva Pharmaceuticals announced...
10/09/2026
Psych Congress Network
FDA Alerts
10/08/2026
Maria Mantas
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug Administration (FDA) granted 510(k) clearance for Motivista, the first treatment specifically authorized for negative symptoms of schizophrenia in adults.
The US Food and Drug...
10/08/2026
Psych Congress Network